Shilpa Medicare’s wholly owned subsidiary - Koanna Healthcare, UK, has received marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (UKMHRA) for the IMATINIB TABLETS in multiple strengths of 100 mg and 400 mg.
The marketing authorization application for this generic product is made through decentralized procedure in 15 EU member states, which involves major European countries like UK, Germany, Netherlands, France, Czech Republic, Belgium, Ireland, Romania etc. Out of 15 member states the first approval is received from UKMHRA. Approvals from remaining member states will follow.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
